Source 1review2018Nature Communications
Toolkit/passively targeted nanocarriers
passively targeted nanocarriers
Also known as: NCs, passively targeted NCs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
only 15 passively targeted nanocarriers (NCs) have been approved for clinical use
Usefulness & Problems
Why this is useful
Passively targeted nanocarriers are delivery systems used to carry cancer therapeutics to tumors without an active targeting ligand-based recognition step. The abstract frames them as the clinically more advanced nanocarrier class.; cancer therapeutic delivery; passive tumor targeting
Source:
Passively targeted nanocarriers are delivery systems used to carry cancer therapeutics to tumors without an active targeting ligand-based recognition step. The abstract frames them as the clinically more advanced nanocarrier class.
Source:
cancer therapeutic delivery
Source:
passive tumor targeting
Problem solved
They aim to improve delivery of cancer therapeutics through nanocarrier-based tumor targeting strategies.; packaging and delivering cancer therapeutics using nanocarrier systems
Source:
They aim to improve delivery of cancer therapeutics through nanocarrier-based tumor targeting strategies.
Source:
packaging and delivering cancer therapeutics using nanocarrier systems
Problem links
packaging and delivering cancer therapeutics using nanocarrier systems
LiteratureThey aim to improve delivery of cancer therapeutics through nanocarrier-based tumor targeting strategies.
Source:
They aim to improve delivery of cancer therapeutics through nanocarrier-based tumor targeting strategies.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
Translation ControlTechniques
No technique tags yet.
Target processes
translationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
translation to clinical use is difficult
The abstract indicates that passive targeting has not translated broadly, with only a limited number of approved products despite many pre-clinical studies.; clinical success remains limited despite many pre-clinical studies
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review states that no actively targeted nanocarriers had advanced past clinical trials at the time of publication.
The review states that only 15 passively targeted nanocarriers have been approved for clinical use.
approved nanocarrier count 15 nanocarriers
The review proposes criteria and considerations for development of novel actively targeted nanocarriers.
The review frames a gap between many successful pre-clinical targeted delivery studies and limited clinical translation and success.
Approval Evidence
1 source2 linked approval claimsfirst-pass slug passively-targeted-nanocarriers
only 15 passively targeted nanocarriers (NCs) have been approved for clinical use
Source:
clinical translation statussupports
The review states that only 15 passively targeted nanocarriers have been approved for clinical use.
Source:
translation gapsupports
The review frames a gap between many successful pre-clinical targeted delivery studies and limited clinical translation and success.
Source:
Comparisons
Source-stated alternatives
The review contrasts passive targeting with actively targeted nanocarriers.
Source:
The review contrasts passive targeting with actively targeted nanocarriers.
Source-backed strengths
has achieved some clinical approvals compared with active targeting approaches
Source:
has achieved some clinical approvals compared with active targeting approaches
Compared with actively targeted nanocarriers
The review contrasts passive targeting with actively targeted nanocarriers.
Shared frame: source-stated alternative in extracted literature
Strengths here: has achieved some clinical approvals compared with active targeting approaches.
Relative tradeoffs: clinical success remains limited despite many pre-clinical studies.
Source:
The review contrasts passive targeting with actively targeted nanocarriers.
Compared with lipid nanoparticles
The review contrasts passive targeting with actively targeted nanocarriers.
Shared frame: source-stated alternative in extracted literature
Strengths here: has achieved some clinical approvals compared with active targeting approaches.
Relative tradeoffs: clinical success remains limited despite many pre-clinical studies.
Source:
The review contrasts passive targeting with actively targeted nanocarriers.
Ranked Citations
- 1.